What did @callmenychelle actually say?
She reported four distinct effects within her first week on tirzepatide (Zepbound): a quieting of ADHD-related racing thoughts roughly two hours after her first injection, dramatically improved sleep with fewer nighttime wake-ups, near-complete appetite suppression for about five days, and reduced alcohol tolerance by day six. She was careful to frame these as personal observations and didn't make sweeping medical claims. Credit where it's due: the "I'm just sharing my experience" framing is more honest than most GLP-1 content on TikTok.
The specific timeline she describes, effects noticed around two and a half hours post-injection on day one, is worth examining. Tirzepatide's peak plasma concentration occurs around 8 to 72 hours post-dose depending on the individual, so a subjective cognitive shift at 2.5 hours is plausible but sits at the very early end of what pharmacokinetics would predict.
Does the science back this up?
Mostly yes, with some important caveats. The hunger suppression and food noise reduction claims have the strongest evidence base. The ADHD and sleep observations are real phenomena being studied, but the research is still early.
On appetite: tirzepatide acts on both GIP and GLP-1 receptors, and clinical trial data from the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed significant reductions in caloric intake and appetite scores, particularly in the first week. "I wasn't hungry until Friday" aligns with what trial participants reported in early weeks, though hunger typically returns somewhat as the body adapts.
On "food noise" and cognitive quiet: a 2023 qualitative study by Garvey et al. in Obesity described patients on GLP-1 receptor agonists reporting reduced preoccupation with food, sometimes called "food noise." The mechanism likely involves GLP-1 receptors in the hypothalamus and reward-related brain circuits, including the nucleus accumbens. Whether this extends to broader ADHD symptom relief is a separate question.
On sleep: a 2023 analysis by Taxvig et al. published in Sleep Medicine Reviews noted that weight loss itself improves sleep architecture, but some GLP-1 receptor activity may independently modulate sleep quality through central nervous system pathways. One week is too short to attribute sleep improvements to weight loss, so the mechanism here is genuinely unclear.
What did they get wrong (or right)?
The ADHD claim is the most scientifically shaky part of this video, even though it's also the most emotionally compelling. She's not wrong that something happened, but the interpretation needs more scrutiny.
There is no approved indication for tirzepatide in ADHD. A small but growing body of research, including a 2024 commentary by Levin et al. in the Journal of Clinical Psychiatry, has noted anecdotal overlap between GLP-1 therapy and reduced ADHD symptoms, potentially through dopaminergic modulation or simply through reduced metabolic noise. But "potentially" is doing a lot of work there. Placebo response is strong, particularly when someone is excited about a new medication and hyper-aware of their mental state. The timing she describes, relief within hours, is biologically plausible but not proven.
What she got right: reduced alcohol tolerance is documented. A 2023 study by Vendruscolo et al. in the Journal of Clinical Investigation showed GLP-1 receptor agonists reduced alcohol consumption in animal models, and early human data supports this. Feeling drinks "almost immediately" is consistent with altered gastric emptying and possibly central reward pathway modulation.
She also got the food aversion piece right. Not just hunger reduction but loss of interest in previously desired foods is a reported and studied phenomenon, not just "eating less."
What should you actually know?
First-week effects on tirzepatide are real but not representative of the long-term experience. Hunger suppression tends to be strongest in weeks one through four at the starting dose, and many users report its return as the body adjusts, particularly before dose escalation.
The ADHD and cognitive clarity reports are interesting signals, not proven benefits. If you have ADHD and start a GLP-1 medication, don't adjust your existing ADHD treatment based on early subjective impressions. Talk to your prescriber.
The alcohol sensitivity change she describes is clinically significant and under-discussed. Reduced tolerance means the same amount of alcohol hits harder. That's not just a fun side note; it matters for safety, particularly for anyone who drives or takes other sedating medications.
- Sleep improvements in week one are likely multifactorial and may not persist at the same intensity.
- Forgetting to eat is not the same as safe eating. Nutrient intake still matters even when appetite signals are suppressed.
- Her positive framing is her genuine experience. It's also week one at the starting dose. Week eight often looks different.